July 2018
-
Media ReleaseSandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology Early therapeutic intervention is…
-
Media ReleaseNovartis delivers solid growth in second quarter and continues transformation to a focused medicines companyNet sales grew 5% (cc1, +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD 239…
June 2018
-
Media ReleaseSandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritisZessly® (infliximab) matched the reference medicine in terms of safety and efficacy at 54 weeks, even in patients who switched from the reference medicine to Zessly1 Switching from the reference…
-
Media ReleaseSandoz receives positive CHMP opinion for proposed biosimilar adalimumabSandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology Positive CHMP opinion…
May 2018
-
Media ReleaseSandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseasesSandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases European Commission's (EC) approval based on comprehensive…
-
Media ReleaseSandoz receives complete response letter from the US FDA for proposed biosimilar rituximabHolzkirchen, May 2, 2018 — Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing…
April 2018
-
Media ReleaseNovartis delivered a strong first quarter and acted to become a more focused medicines companyNet sales grew 4% (cc1, +10% USD) mainly driven by: Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide Cosentyx was USD 580 million, +35% (cc) with strong growth in…
-
Media ReleaseSandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disordersDeal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O™, potential treatment pending FDA clearance for patients with Opioid Use Disorder treated with…
-
Media ReleaseSandoz outlines plans for next Healthcare Access Challenge (HACk), to support local digital innovationSandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare Publication, which coincides with World…
February 2018
-
Media ReleaseSandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosisGlatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched in the…
-
Media ReleaseSandoz certified as Top Employer Europe 2018Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings in Europe and Russia The annual, international research undertaken by the Top Employers…